ALPN - Alpine Immune Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Alpine Immune Sciences, Inc.

201 Elliott Avenue West
Suite 230
Seattle, WA 98119
United States
206-788-4545
http://www.alpineimmunesciences.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees48

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell H. GoldExec. Chairman & CEO703.25kN/A1968
Dr. Stanford PengPres and Head of R&D650.83kN/A1971
Mr. Paul RickeySr. VP, CFO & Corp. Sec.489.79kN/A1979
Dr. Wayne R. GombotzChief Technology OfficerN/AN/A1959
Dr. Kristine Swiderek Ph.D.Sr. VP of ResearchN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Corporate Governance

Alpine Immune Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.